| __timestamp | Intra-Cellular Therapies, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 12665000 |
| Thursday, January 1, 2015 | 139626 | 20202000 |
| Friday, January 1, 2016 | 93831530 | 32407000 |
| Sunday, January 1, 2017 | 79419009 | 35219000 |
| Monday, January 1, 2018 | 368673 | 36386000 |
| Tuesday, January 1, 2019 | 477121 | 43081000 |
| Wednesday, January 1, 2020 | 1895029 | 39330000 |
| Friday, January 1, 2021 | 8034589 | 43283000 |
| Saturday, January 1, 2022 | 20443000 | 48316000 |
| Sunday, January 1, 2023 | 33745000 | 54634000 |
Unleashing the power of data
In the ever-evolving landscape of biopharmaceuticals, understanding cost efficiency is crucial. This analysis delves into the cost of revenue trends for Intra-Cellular Therapies, Inc. and MiMedx Group, Inc. over the past decade. From 2014 to 2023, Intra-Cellular Therapies, Inc. experienced a significant fluctuation in its cost of revenue, peaking in 2016 with a 350% increase compared to 2014. Meanwhile, MiMedx Group, Inc. demonstrated a more stable trajectory, with a consistent rise, culminating in a 330% increase by 2023.
The data reveals that while Intra-Cellular Therapies, Inc. faced volatility, MiMedx Group, Inc. maintained a steady growth pattern. This insight is pivotal for investors and stakeholders aiming to gauge financial health and operational efficiency in the biopharmaceutical sector. As the industry continues to grow, such analyses will be indispensable for strategic decision-making.
Cost Insights: Breaking Down AbbVie Inc. and Intra-Cellular Therapies, Inc.'s Expenses
Amgen Inc. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Biogen Inc. and Intra-Cellular Therapies, Inc.'s Expenses
BeiGene, Ltd. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Viatris Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Grifols, S.A.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Cytokinetics, Incorporated
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Analyzing Cost of Revenue: Pharming Group N.V. and MiMedx Group, Inc.
Cost of Revenue Comparison: Cytokinetics, Incorporated vs MiMedx Group, Inc.